Navigation Links
Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease
Date:6/18/2012

DUBLIN, June 18, 2012 /PRNewswire/ -- Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial. All of the abstracts were presented at The 16th International Congress of Parkinson's Disease and Movement Disorders, June 17-21 in Dublin, Ireland.

LCIG is currently approved in 40 countries. In the U.S., LCIG is an investigational therapy that is currently being evaluated in patients with advanced Parkinson's disease in additional Phase 3 clinical trials. In these trials, levodopa-carbidopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of LCIG during awake hours.

Long-Term Safety and Tolerability
In a 54 week open-label safety and tolerability study of 354 patients with advanced Parkinson's disease, the primary endpoint of safety showed adverse events (AEs) were mostly mild to moderate, were generally associated with the Percutaneous Endoscopic Gastrostomy (PEG) tube placement procedure and its complications, were transient, and resolved over time.

In the secondary endpoint analysis from the open-label study, patients experienced an average daily "off" time of 6.7 hours, and 7.7 hours of "on" time without troublesome dyskinesia at baseline. "Off" time refers to periods of poor mobility, slowness and stiffness experienced by patients with Parkinson's disease, while "on" time refers to periods of good motor symptom control. At week 54, mean daily "off" time had decreased an average of 4.5 h
'/>"/>

SOURCE Abbott
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
2. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
3. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
4. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
5. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
6. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
10. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... PHILADELPHIA, Jan. 20, 2011 The U.S. Food ... System Drugs Advisory Committee decided today that it ... this time based on the currently available data ... of Amyvid conditional on a reader training program ...
... Inc. (Nasdaq: ELGX ), developer of minimally invasive ... release of its fourth quarter and full year 2010 financial ... after the close of the market. Endologix will ... 5:00 p.m. ET / 2:00 p.m. PT to discuss the ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Endologix to Report Fourth Quarter and Full Year 2010 Financial Results on February 22, 2011 2
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... 3, 2007) Two methods that permit scientists ... in this months release of Cold Spring Harbor ... online ( www.cshprotocols.org ), describe how to fluorescently tag ... combined with sophisticated imaging methods, permit scientists to visualize ...
... with Las Vegas and Tucson Marathon Runners, PLEASANT ... an event to prevent inflammation and pain, but at ... by researchers at,Appalachian State University and Vanderbilt University, published ... taking ibuprofen,before exercise may be unhealthy in the long ...
... to,build on the issue of requiring physicians to ... Management Association,(PCMA) today announced a new round of ... Last year, Dr. Bootman co-chaired an Institute of ... using e-prescribing by,2010 to help reduce the estimated ...
... ... -, JEFFERSON CITY, Mo., ... -,Missouri Military Family Relief Fund, which will help support the needs of,more than ... for the central market area at,TriWest, will present the check to the Adjutant ...
... Dec. 3 Operon,Biotechnologies, Eurofins MWG and Eurofins ... - announced today that they have agreed to ... leader in the competitive,custom oligonucleotide market. With about ... high-throughput production facilities in all major markets (North,America, ...
... retires; Mike Gallagher, President and CEO of ... Dec. 3 AvMed Health Plans said today ... to retire December 31,2007. As a result, Mike ... HealthCare, who already has overall leadership and strategic,responsibilities ...
Cached Medicine News:Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2Health News:MWG and Operon Are Joining Forces 2Health News:AvMed Announces Senior Leadership Changes 2
For use with cushioned neckband....
... PVC siliconized. Stainless steel spiral reinforced. X-ray ... use. Adjustable Flange: The flange can be ... the thickness of the cervical soft tissue. ... the flange is tightly connected to the ...
... The permanent flexible tube ... of the neck flange helps ... neck, chin, and stoma, enhancing ... ,Bivona® FlexTend™ tracheostomy tubes ...
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
Medicine Products: